Dr. Paul Yeh
Honorary
The Sir Peter MacCallum Department of Oncology
7 Scholarly works
3 Projects
HIGHLIGHTS
2021
Journal article
Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
DOI: 10.3324/haematol.2020.2604482020
Research Grant
Blood based detection and monitoring of pre-malignant clonal haematopoiesis to predict clinical outcomes in the immunocompromised.
2020
Journal article
HBO1 is required for the maintenance of leukaemia stem cells
DOI: 10.1038/s41586-019-1835-62019
Conference Proceedings
BTK Leu528Trp-a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
DOI: 10.1182/blood-2019-1254882019
Journal article
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
DOI: 10.1038/s41467-019-10652-92019
Research Grant
INFLUENCES OF CLONAL HAEMATOPOIESIS IN ALLOGENEIC STEM CELL TRANSPLANTATION
2018
Research Grant
INFLUENCES OF CLONAL HAEMATOPOIESIS IN ALLOGENEIC BONE MARROW TRANSPLANTATION
RECENT SCHOLARLY WORKS
2019
Journal article
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
DOI: 10.1038/s41591-018-0243-z2018
Conference Proceedings
A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)
DOI: 10.1182/blood-2018-99-117089Journal article
Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
DOI: 10.21203/rs.3.rs-106576/v1